Your browser doesn't support javascript.
loading
Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score-weighted comparative cohort study.
Soleimani, Maryam; Zou, Kevin; Sunderland, Katherine; Struss, Werner; Eigl, Bernie J; Nappi, Lucia; Kollmannsberger, Christian K; Finch, Daygen; Noonan, Krista; Vergidis, Joanna; Zulfiqar, Muhammad; Chi, Kim N; Khalaf, Daniel J.
Afiliação
  • Soleimani M; Department of Medicine, Medical Oncology Division, BC Cancer, Vancouver Centre, University of British Columbia, Vancouver, BC, Canada.
  • Zou K; Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Sunderland K; Department of Biostatistics, BC Cancer Vancouver Centre, Vancouver, BC, Canada.
  • Struss W; Department of Urology, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
  • Eigl BJ; Department of Medicine, Medical Oncology Division, BC Cancer, Vancouver Centre, University of British Columbia, Vancouver, BC, Canada; Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada.
  • Nappi L; Department of Medicine, Medical Oncology Division, BC Cancer, Vancouver Centre, University of British Columbia, Vancouver, BC, Canada; Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada.
  • Kollmannsberger CK; Department of Medicine, Medical Oncology Division, BC Cancer, Vancouver Centre, University of British Columbia, Vancouver, BC, Canada; Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada.
  • Finch D; BC Cancer Centre for the Southern Interior, Kelowna, BC, Canada.
  • Noonan K; BC Cancer Fraser Valley Centre, Surrey, BC, Canada.
  • Vergidis J; BC Cancer Vancouver Island Centre, Victoria, BC, Canada.
  • Zulfiqar M; BC Cancer Vancouver Island Centre, Victoria, BC, Canada.
  • Chi KN; Department of Medicine, Medical Oncology Division, BC Cancer, Vancouver Centre, University of British Columbia, Vancouver, BC, Canada; Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada.
  • Khalaf DJ; Department of Medicine, Medical Oncology Division, BC Cancer, Vancouver Centre, University of British Columbia, Vancouver, BC, Canada. Electronic address: daniel.khalaf@bccancer.bc.ca.
Eur J Cancer ; 152: 215-222, 2021 07.
Article em En | MEDLINE | ID: mdl-34130153
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Feniltioidantoína / Benzamidas / Neoplasias de Próstata Resistentes à Castração / Androstenos / Nitrilas Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged80 / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Feniltioidantoína / Benzamidas / Neoplasias de Próstata Resistentes à Castração / Androstenos / Nitrilas Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged80 / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article